An Economic Analysis of Mumps Vaccination in Fiji: Static Model Simulation of Routine Measles-Mumps-Rubella (MMR) Vaccination Instead of Current Measles-Rubella (MR) Vaccination
- PMID: 35162883
- PMCID: PMC8835634
- DOI: 10.3390/ijerph19031861
An Economic Analysis of Mumps Vaccination in Fiji: Static Model Simulation of Routine Measles-Mumps-Rubella (MMR) Vaccination Instead of Current Measles-Rubella (MR) Vaccination
Abstract
Mumps remains endemic in Fiji, with 7802 cases reported between 2016 and 2018. The introduction of mumps vaccination has been discouraged due to perceptions of mumps as a self-limited disease and the perceived high cost of mumps vaccines. We estimated the benefits and costs of introducing a mumps vaccination program in Fiji. First, we estimated the burden of mumps and mumps-related complications in Fiji based on the reported cases in the Fiji National Notifiable Disease Surveillance System between 2016 and 2018. We then developed a static simulation model with stable mumps herd immunity after routine measles-mumps-rubella (MMR) vaccination. Finally, we compared the estimated economic burden of mumps with current MR vaccination and the assumptive burden of the stable-state simulation model after routine MMR vaccination. The benefit-cost ratios (BCRs) were 2.65 from the taxpayer view and 3.00 from the societal view. A probabilistic sensitivity analysis indicated that the 1st and 99th percentiles of BCRs were 1.4 and 5.2 from the taxpayer's perspective and 1.5 and 6.1 from the societal perspective. From both the taxpayer and societal perspectives, the probability of BCRs greater than 1.0 was 100%. A routine MMR program has value for money from both the taxpayer and societal perspectives. MMR vaccination should be urgently introduced in Fiji.
Keywords: Fiji; cost benefit analysis; mumps vaccination; static model.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.Vaccine. 2013 May 31;31(24):2661-6. doi: 10.1016/j.vaccine.2013.04.014. Epub 2013 Apr 17. Vaccine. 2013. PMID: 23602654
-
An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.J Infect Dis. 2004 May 1;189 Suppl 1:S131-45. doi: 10.1086/378987. J Infect Dis. 2004. PMID: 15106102
-
Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.PLoS One. 2014 Feb 20;9(2):e89361. doi: 10.1371/journal.pone.0089361. eCollection 2014. PLoS One. 2014. PMID: 24586717 Free PMC article. Clinical Trial.
-
Measles, mumps, rubella prevention: how can we do better?Expert Rev Vaccines. 2021 Jul;20(7):811-826. doi: 10.1080/14760584.2021.1927722. Epub 2021 Jun 7. Expert Rev Vaccines. 2021. PMID: 34096442 Review.
-
MMR vaccination and disease elimination: the Finnish experience.Expert Rev Vaccines. 2010 Sep;9(9):1045-53. doi: 10.1586/erv.10.99. Expert Rev Vaccines. 2010. PMID: 20822347 Review.
Cited by
-
Vaccination Against Mumps, Aren't We Late Already?JNMA J Nepal Med Assoc. 2024 Jul 31;62(276):555-557. doi: 10.31729/jnma.8731. JNMA J Nepal Med Assoc. 2024. PMID: 39369395 Free PMC article.
-
Mumps outbreak in Zimbabwe: The case for universal MMR vaccination in Africa.Vaccine X. 2024 Nov 17;21:100586. doi: 10.1016/j.jvacx.2024.100586. eCollection 2024 Dec. Vaccine X. 2024. PMID: 39633854 Free PMC article. No abstract available.
-
Bibliometric Analysis of Global Scientific Literature on Mumps Vaccines.Cureus. 2025 Jul 29;17(7):e88976. doi: 10.7759/cureus.88976. eCollection 2025 Jul. Cureus. 2025. PMID: 40896021 Free PMC article. Review.
References
-
- WHO . Global Immunization Coverage 2018. World Health Organization; Geneva, Switzerland: 2019. [(accessed on 17 January 2022)]. Available online: https://www.who.int/news-room/fact-sheets/detail/immunization-coverage.
-
- WHO . Mumps Virus Vaccine WHO Position Paper. World Health Organization; Geneva, Switzerland: 2007.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical